0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > TL1A

TL1A

Brief Information

Name:Tumor necrosis factor superfamily member 15
Target Synonym:VEGI192A,Vascular Endothelial Cell Growth Inhibitor,TNF Superfamily Ligand TL1A,TNFSF15,Tumor Necrosis Factor (Ligand) Superfamily, Member 15,Vascular Endothelial Growth Inhibitor-192A,VEGI,TL1A,Tumor Necrosis Factor Ligand 1B,TNLG1B,TNF Superfamily Member 15,Tumor Necrosis Factor Superfamily Member 15,TL1,TNF Ligand-Related Molecule 1,Tumor Necrosis Factor Ligand Superfamily Member 15,MGC129934,MGC129935
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

TLA-H52Q1-SPR
 TL1A SPR

Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) immobilized on CM5 Chip can bind Biotinylated Human TL1A Protein, His,Avitag (Cat. No. TLA-H52Q1) with an affinity constant of 97.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

TLA-H5243-SPR
 TL1A SPR

Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) immobilized on CM5 Chip can bind Human TL1A, His Tag (Cat. No. TLA-H5243) with an affinity constant of 45.8 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

TL1A, VEGI-251, TNFSF15

Background

TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RVT-3101 PF-06480605 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease Details
PRA-023 PRA-023 Phase 2 Clinical Prometheus Biosciences Inc Inflammatory Bowel Diseases; Lung Diseases, Interstitial; Colitis, Ulcerative; Scleroderma, Diffuse; Crohn Disease Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Nachricht schicken